Mavenir Opens New Center of Innovation in Stockholm
3.10.2019 15:00:00 EEST | Business Wire | Press release
Mavenir, the industry’s only end-to-end cloud-native Network Software Provider and a leader in accelerating software network transformation for communications service providers (CSPs), has opened another Center of Innovation, now in Stockholm. The Center will focus on Mavenir’s innovative and open virtualized Radio Access Network (vRAN) development, both S/W and H/W, as well as innovation on next generation platforms for 5G and IoT for Service Providers, Industry and Enterprises.
The ambition is to leverage the innovation center to evolve and scale Mavenir’s disruptive approach for next generation networks (5G and 4G) with fully virtualized RAN that will be led by Mikael Rylander, SVP/GM RAN Business.
Mavenir unveiled plans to create, deploy and scale solutions for Digital Enterprises, IoT and Private Networks, by investing in the creation of an ecosystem of partners and customers, and tapping into Sweden’s vibrant pool of high-tech competence in an initiative led by Aniruddho Basu, SVP/GM of Emerging Business.
Pardeep Kohli, Mavenir’s President and CEO, said, “We establish these centers of excellence in areas where there is a true hub of innovation. We are pleased to have a strong presence in Stockholm, where we can attract top talent and leverage the technical knowledge in key areas, a Twin-City to Dallas, Texas.”
In addition, today Mavenir announces a formal enterprise technology partnership with the Deep Tech hub THINGS and a partnership with the Swedish IoT alliance (SMSE).
Magnus Melander, founder of THINGS and SMSE, said, “We are excited that Mavenir is coming on board the THINGS platform, as well as becoming a partner of SMSE. THINGS and SMSE sit at the intersection of creative and innovative startups, established and technology-focused enterprises and industries, and a select handful of technology providers – the trifecta will drive innovation in technology as well as business models, and foster a true collaborative ecosystem for 5G and IoT, for digital transformation.”
Today, Mavenir formally inaugurated its Stockholm office as Center of Innovation highlighting two themes. First, to drive innovation in the OpenRAN space for virtualized radio access networks (vRAN) for 4G and 5G, and second, to drive the ‘Twin-City’ concept of innovation between Stockholm and Dallas (location of Mavenir HQ) for tapping into the creativity of technology startups, academia, and digital enterprises and industries. Both Dallas and Stockholm have a history of disruption, innovation and creativity in mobile networks. Stockholm has, in the last few years, developed a thriving ecosystem of startups, developers, investors, enterprises and industries that are forging new ground in digital transformation – both in technology and business.
The new Center of Innovation in Stockholm builds on Mavenir’s growing global presence with its network of dedicated Centers of Excellence. It joins the 5G Center of Excellence as well as the AI/Machine Learning (AI/ML) Center of Excellence both in EMEA, and the NFV/SDN Cloud Centers in US, India, & Shanghai.
About Mavenir:
Mavenir is the industry's only end-to-end, cloud-native Network Software Provider focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN – Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC, and virtualized RAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 130 countries, serving over 50% of the world’s subscribers.
We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. Learn more at mavenir.com.
Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.
Copyright © 2019 Mavenir Systems, Inc. All Rights Reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191003005022/en/
Contact information
Maryvonne Tubb
Mavenir
PR@mavenir.com
Loren Guertin
MatterNow
mavenir@matternow.com
Kevin Taylor
GlobalResultsPR
mavenir@globalresultspr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom